Eric Qiong Wu
Ph.D., pharmacoeconomics and policy, M.S., health care regulation and law, and M.A., economics, University of Southern California; B.S., Peking University
Summary of Experience:
Dr. Wu is a health economist specializing in health economics, outcomes, and market access issues related to pharmaceuticals and biologics. He has broad experience consulting to pharmaceutical and device companies, payers, and government agencies in North America, Europe, and Asia. Dr. Wu has extensive experience in the development of health economics and outcomes research strategy, analysis of medical claims and clinical trial data, patient chart review, patient surveys and physician surveys, and economic modeling to support treatment guideline development; global formulary and reimbursement submission; step therapy design; appropriate generics and biosimilars use; and investigations in comparative effectiveness, direct and indirect resource utilization and costs, work loss, quality of life, treatment pattern, disease prevalence, and adverse events. His interests also include developing new methods and statistical tests to address challenges in health care research. Dr. Wu is an adjunct professor at Nankai University in China and sits on the advisory board of the Health Economic Evaluation Center of the Chinese Medical Doctor Association.